Avastin: all it's cracked up to be?

Article

Last year, Philip Rosenfeld of the Bascom Palmer Eye Institute in Miami, USA, announced some findings that made the ophthalmology community stand to attention. He claimed that intravitreal administration of the cancer agent, Avastin (bevacizumab), in wet age-related macular degeneration (AMD) patients yielded very positive results. Since then, industry journals have been inundated with reports of the benefits of this agent in an ophthalmic setting.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Subscribe Now!
Recent Videos
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
Charles Wykoff, MD, PhD, discusses his Floretina ICOOR presentation topic, retinal non-perfusion in diabetic retinopathy, with David Hutton, editor of Ophthalmology Times
Quan Dong Nguyen, MD, MSc, of the Byers Eye Institute at Stanford University School of Medicine, discusses his presentation on Stargardt disease at the American Academy of Ophthalmology meeting
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Related Content
LuxIA receives CE-MDR certification

LuxIA receives CE-MDR certification

Sydney M Crago
May 1st 2025
Article

LuxIA is designed to screen adult diabetic patients for more-than-mild diabetic retinopathy.

PHOTON Results and Their Relation to DME Patients in Your Practice

PHOTON Results and Their Relation to DME Patients in Your Practice

July 25th 2024
Podcast

John Kitchens, MD, is joined by Diana Do, MD, to discuss the PHOTON trial results and their relation to patients with diabetic macular oedema in clinical practice.

A photo of a boardroom with a presenter's projector screen, and easel, and many chairs. Concept image for Beth Marsh appointed CCO chief commercial officer of Neurotech Pharmaceuticals, ophthalmic industry news update. Image credit: ©nnpp's Images – canva.com

Neurotech appoints Beth Marsh as chief commercial officer ahead of US product launch

Kassi Filkins
April 22nd 2025
Article

The US FDA recently approved revakinagene taroretcel-lwey (ENCELTO) for the treatment of idiopathic macular telangiectasia type 2 (MacTel)

PULSAR Results and Their Relation to nAMD Patients in Your Practice

PULSAR Results and Their Relation to nAMD Patients in Your Practice

July 24th 2024
Podcast

John Kitchens, MD, is joined by David Brown, MD, to discuss the PULSAR study results and their relation to patients with neovascular age-related macular degeneration in clinical practice.

A young person with short androgynous hair sits in a waiting room, looking thoughtful. Concept image for racial groups in clinical trials and representation in studies. Image credit: ©wayhome.studio – stock.adobe.com

DMO study meta-analysis illuminates how racial subgroups are underrepresented in clinical trials

Lynda Charters
April 17th 2025
Article

The study aimed to clarify how race affects visual outcomes for patients with diabetic macular oedema treated with ranibizumab

Two hands reach towards a logo which says "AI," for artificial intelligence. Concept image for AI screenings for neovascular age-related macular degeneration. Image credit: ©deagreez – stock.adobe.com

Artificial intelligence analyses biomarker changes in neovascular AMD treated with faricimab

Lynda Charters
April 17th 2025
Article

The phase 3 LUCERNE and TENAYA trials suggested that faricimab may allow clinicians to extend the interval between injections to up to 16 weeks after an initial loading phase

© 2025 MJH Life Sciences

All rights reserved.